On this page
Back to topADARx Pharmaceuticals ADRX
ADARx Pharmaceuticals listed on Nasdaq on 28 Sep 2026 and is not in the S&P 500. It is worth $1.6 billion. Its price history starts on 25 Sep 2026. Its board is not in our data yet.
- CEO
- Zhen Li
- Listed
- 28 Sep 2026 on Nasdaq, IPO filings and terms
- Headquarters
- San Diego, CA
- Market cap
- $1.6B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Financial history
Twelve months to 30 Sep 2026, from ADARx Pharmaceuticals' quarterly filings.
Quarters since Sep 2025
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Sep 2025 to Sep 2026
Not reported for enough quarters.
Not reported for enough quarters.
Not reported for enough quarters.
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $2M | $-28M |
| Sep 2025 | $2M | $-18M |
ADARx Pharmaceuticals' market cap since September 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.6B |
Download ADARx Pharmaceuticals' data as JSON, with the weekly market caps in billions of dollars from 25 Sep 2026.
Board and leadership
Board and officers
ADARx Pharmaceuticals' board is not in our data yet. It listed on 28 Sep 2026 and has not filed a proxy statement. See its 8-K filings.
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $44.4 million in 3 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 28 Sep 2026Buy | Simeon GeorgeDirector | $27M |
| 28 Sep 2026Buy | Carl L. GordonDirector | $16M |
| 28 Sep 2026Buy | Erez ChimovitsDirector | $1.0M |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: ADARx Pharmaceuticals listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.